The Eversense® Continuous Glucose Monitoring System (CGM) is the first and only CGM system to feature an implantable glucose sensor, a removable and rechargeable smart transmitter, and long-term continuous monitoring. The Eversense CGM System is approved by the U.S. Food and Drug Administration (FDA) for continually measuring glucose levels in adults (18 years and older) with diabetes for up to 90 days, making it the longest-lasting CGM available in the U.S.¹

**How The System Works**

The Eversense CGM System provides real-time glucose readings, glucose trend information, and alerts for the detection and prediction of episodes of high and low glucose (hyperglycemia and hypoglycemia). The Eversense CGM System has three main components that work together:

- **The Eversense Sensor** is a novel fluorescence-based sensor that is inserted subcutaneously in the upper arm by a physician in a brief in-office procedure.
  - Proven to continuously and accurately measure glucose levels throughout 90 days of wear, compared to traditional sensors that last only seven to 10 days
    - Designed to be inserted only four times a year, eliminating the pain and hassle of weekly or bi-weekly sensor self-insertion
  - Communicates information to the smart transmitter via near frequency communication (NFC) technology
  - Measures real-time glucose values every five minutes
  - The sensor’s accuracy is not impacted by compression from external physical pressure or exercise

- **The Eversense Smart Transmitter** is worn over the sensor to facilitate data communication, and is secured to the skin with a gentle, silicone-based adhesive patch that is replaced daily to ensure comfort and minimize skin reactions.
  - Light, discreet, and comfortable-to-wear, it is the only CGM transmitter that can be removed and recharged without wasting a sensor
    - Fully recharges in just 15 minutes and can be used for 36 hours on a single charge
  - Receives data wirelessly from the sensor and sends the information via Bluetooth to the user’s mobile device
  - Provides on-body vibratory alerts to warn the user of impending or current hypo or hyperglycemic event for added safety

- **The Eversense Mobile App** displays glucose values, trends, and alerts on a user’s iOS® or Android® smartphone, as well as the Apple® Watch, allowing patients to discreetly check their data.
  - Configured to deliver visual and audible alerts, offering glycemic awareness even during sleep, providing an additional safety advantage
  - Allows user to customize settings to trigger alerts based on glucose level and other data, and stores data in secure cloud server
  - Enables patients to allow family members or caregivers to remotely view the patient’s glucose readings and alerts from the family members’ or caregivers’ own mobile devices for added security and knowledge
Impact on Patients

The Eversense CGM System has unique features addressing many barriers to CGM use and provides new levels of freedom and flexibility compared to traditional CGM systems.

Several studies (PRECISE, PRECISE II, PRECISION) have been conducted on Eversense in the U.S. and in Europe. PRECISE II, a U.S. pivotal study for the FDA’s approval of the Eversense System, demonstrated a strong safety and sustained accuracy during 90 days of continuous sensor wear. Including more than 16,000 paired data points and more than two million sensor glucose readings, PRECISE II is the largest continuous single-sensor study in the world.

- Study participants reported improvements in all domains of diabetes-related stress, with the ability to easily see the number and trend direction of glucose values cited as a particular benefit.
- Nine out of 10 study participants said the Eversense CGM System helped minimize the burden of diabetes in their life and 85% reported increased confidence in diabetes control.
- 84% of study participants said they would want to be inserted again with the Eversense sensor, and no infections or adhesive skin irritations were reported.
- 92% of study participants indicated that they did not experience pain or discomfort when using the sensor.

Specification Overview

- Indicated for: Adults 18 years and above
- Sensor life: Up to 90 days
- Sensor technology: Fluorescence-based
- Sensor dimensions: 3.5 mm x 18.3 mm
- Mobile app availability: iOS, Android, Apple Watch
- Transmitter properties: Removable, rechargeable
- Transmitter dimensions: 37.6 mm Long; 48.0 mm Wide; 8.8 mm Thick
- Transmitter water resistance: 3 feet deep up to 30 minutes
- Calibration: 2 fingerstick calibrations/day, 10 to 14 hours apart
- Frequency of readings (interval): 5 minutes
- Accuracy of readings: MARD\(^i\) of 8.5% based on the PRECISE II study

Product images are available upon request. For more information, please visit: EversenseDiabetes.com.

---

1 The Eversense CGM System is intended to complement, not replace, fingerstick blood glucose monitoring. The sensor insertion and removal is performed by a physician. The Eversense CGM System is a prescription device; patients should talk to their doctor to learn more. For important safety information, see https://eversensediabetes.com/safety-info/.

2 MARD (Mean Absolute Relative Difference) is a common measure of accuracy. A lower value indicates closer accuracy to a reference value.